As current staging systems for cancer are typically found through anatomical evaluations of the disease, stratification of patients for treatment and further therapy strategies prove difficult. Much potential remains in cancer biomarker research for the identification of prognostic gene expression signatures capable of classifying tumor subgroups via their biological counterparts. With the advancements in genomic and transcriptomic technologies, researchers are making great discoveries in cancer biomarkers for detection, prediction of therapeutic response and prognoses of cancer. Recent research highlights a new cuproptosis (copper-induced death) related immune checkpoint gene signature recently investigated as a potential biomarker for anticancer therapy for hepatocellular carcinoma. 

Recommended Posts